Virtual Reality Exhibit Simulates Cancer Fatigue

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

LOS ANGELES--Visitors to the Exhibitor’s Hall at this year’s ASCO meeting had the opportunity to walk in the shoes of a patient with cancer-related fatigue at Ortho-Biotech’s In My Steps virtual reality experience, developed in cooperation with cancer patients and the Fatigue Coalition.

LOS ANGELES--Visitors to the Exhibitor’s Hall at this year’s ASCO meeting had the opportunity to walk in the shoes of a patient with cancer-related fatigue at Ortho-Biotech’s In My Steps virtual reality experience, developed in cooperation with cancer patients and the Fatigue Coalition.

For this virtual journey, you sit in a special chair outfitted with pedals. A technician fits you with a virtual reality helmet (see Figure) that places you in the simulated house, and in the shoes, of a fatigued cancer patient. Using the pedals to "walk" and a hand-guided pointer to direct your movements, you guide the patient through simple tasks made challenging by the resistant pedals that slow your steps. Just making a cup of tea becomes maddeningly difficult as the kettle whistles, the doorbell rings, and an impatient delivery man leaves before you can reach the door. The experience, of course, cannot simulate the debilitating fatigue that many cancer patients describe. In one survey, 29% said they had difficulty just getting out of bed, and 24% were too tired to eat. It does, however, reveal the frustrations such patients feel.

In My Steps is traveling to cancer centers as part of 1-day fatigue awareness workshops for physicians and nurses. To schedule an event, call 1-800-776-2748.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content